A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study investigates the effectiveness and safety of 12 weeks of treatment with
JNJ-16269110 (R256918), in overweight and obese patients. The primary measure of
effectiveness is the change in body weight at a clinically relevant dosage level during
treatment. Additional measures include body mass index (BMI), DEXA (dual X-ray absorptiometry
which is a specialized x-ray test that measures body composition), fasting glucose, lipid
levels, and blood pressure. Safety assessments performed during the trial include laboratory
tests, vital sign measurements, and adverse event reporting.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.